• Je něco špatně v tomto záznamu ?

Amino acid derivatives as transdermal permeation enhancers

B. Janůšová, B. Skolová, K. Tükörová, L. Wojnarová, T. Simůnek, P. Mladěnka, T. Filipský, M. Ríha, J. Roh, K. Palát, A. Hrabálek, K. Vávrová,

. 2013 ; 165 (2) : 91-100.

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13024150

Transdermal permeation enhancers are compounds that temporarily decrease skin barrier properties to promote drug flux. In this study, we investigated enhancers with amino acids (proline, sarcosine, alanine, β-alanine, and glycine) attached to hydrophobic chain(s) via a biodegradable ester link. The double-chain lipid-like substances displayed no enhancing effect, whereas single-chain substances significantly increased skin permeability. The proline derivative l-Pro2 reached enhancement ratios of up to 40 at 1% concentration, which is higher than that of the well-established and standard enhancers Azone, DDAIP, DDAK, and Transkarbam 12. No stereoselectivity was observed. l-Pro2 acted synergistically with propylene glycol. Infrared studies revealed that l-Pro2 forms a separate liquid ordered phase in the stratum corneum lipids and has no significant effect on proteins. l-Pro2 action was at least partially reversible as measured by skin electrical impedance. Toxicity in keratinocyte (HaCaT) and fibroblast (3T3) cell lines showed IC(50) values ranging from tens to hundreds of μM, which is comparable with standard enhancers. Furthermore, l-Pro2 was rapidly decomposed in plasma. In vivo transdermal absorption studies in rats confirmed the enhancing activity of l-Pro2 and suggested its negligible skin toxicity and minimal effect on transepidermal water loss. These properties make l-Pro2 a promising candidate for potential clinical use.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13024150
003      
CZ-PrNML
005      
20130710113056.0
007      
ta
008      
130703s2013 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jconrel.2012.11.003 $2 doi
035    __
$a (PubMed)23154194
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Janůšová, Barbora $u Charles University in Prague, Hradec Králové, Czech Republic.
245    10
$a Amino acid derivatives as transdermal permeation enhancers / $c B. Janůšová, B. Skolová, K. Tükörová, L. Wojnarová, T. Simůnek, P. Mladěnka, T. Filipský, M. Ríha, J. Roh, K. Palát, A. Hrabálek, K. Vávrová,
520    9_
$a Transdermal permeation enhancers are compounds that temporarily decrease skin barrier properties to promote drug flux. In this study, we investigated enhancers with amino acids (proline, sarcosine, alanine, β-alanine, and glycine) attached to hydrophobic chain(s) via a biodegradable ester link. The double-chain lipid-like substances displayed no enhancing effect, whereas single-chain substances significantly increased skin permeability. The proline derivative l-Pro2 reached enhancement ratios of up to 40 at 1% concentration, which is higher than that of the well-established and standard enhancers Azone, DDAIP, DDAK, and Transkarbam 12. No stereoselectivity was observed. l-Pro2 acted synergistically with propylene glycol. Infrared studies revealed that l-Pro2 forms a separate liquid ordered phase in the stratum corneum lipids and has no significant effect on proteins. l-Pro2 action was at least partially reversible as measured by skin electrical impedance. Toxicity in keratinocyte (HaCaT) and fibroblast (3T3) cell lines showed IC(50) values ranging from tens to hundreds of μM, which is comparable with standard enhancers. Furthermore, l-Pro2 was rapidly decomposed in plasma. In vivo transdermal absorption studies in rats confirmed the enhancing activity of l-Pro2 and suggested its negligible skin toxicity and minimal effect on transepidermal water loss. These properties make l-Pro2 a promising candidate for potential clinical use.
650    _2
$a buňky 3T3 $7 D016475
650    _2
$a aplikace kožní $7 D000279
650    _2
$a aminokyseliny $x chemie $x metabolismus $x farmakologie $x toxicita $7 D000596
650    _2
$a zvířata $7 D000818
650    _2
$a buněčné linie $7 D002460
650    _2
$a stabilita léku $7 D004355
650    _2
$a lidé $7 D006801
650    _2
$a keratinocyty $x účinky léků $x metabolismus $7 D015603
650    _2
$a myši $7 D051379
650    _2
$a permeabilita $x účinky léků $7 D010539
650    _2
$a krevní plazma $x metabolismus $7 D010949
650    _2
$a prolin $x analogy a deriváty $x metabolismus $x farmakologie $x toxicita $7 D011392
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a kůže $x účinky léků $x metabolismus $7 D012867
650    _2
$a kožní absorpce $x účinky léků $7 D012869
650    _2
$a prasata $7 D013552
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Skolová, Barbora $u -
700    1_
$a Tükörová, Katarína $u -
700    1_
$a Wojnarová, Lea $u -
700    1_
$a Simůnek, Tomáš $u -
700    1_
$a Mladěnka, Přemysl $u -
700    1_
$a Filipský, Tomáš $u -
700    1_
$a Ríha, Michal $u -
700    1_
$a Roh, Jaroslav $u -
700    1_
$a Palát, Karel $u -
700    1_
$a Hrabálek, Alexandr $u -
700    1_
$a Vávrová, Kateřina $u -
773    0_
$w MED00002621 $t Journal of controlled release : official journal of the Controlled Release Society $x 1873-4995 $g Roč. 165, č. 2 (2013), s. 91-100
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23154194 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130703 $b ABA008
991    __
$a 20130710113520 $b ABA008
999    __
$a ok $b bmc $g 987830 $s 822530
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 165 $c 2 $d 91-100 $i 1873-4995 $m Journal of controlled release $n J Controlled Release $x MED00002621
LZP    __
$a Pubmed-20130703
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace